Cerus Corporation Announces Presentations Highlighting INTERCEPT Blood System at the 29th Regional Congress of the ISBT
June 24 2019 - 6:00PM
Business Wire
Cerus Corporation (Nasdaq:CERS) announced today that multiple
abstracts featuring the INTERCEPT Blood System pathogen reduction
technology, including four oral presentations, will be included in
the scientific program at the 29th regional congress of
International Society of Blood Transfusion (ISBT). The ISBT is one
of the premier congresses in the field of transfusion medicine.
This year, the meeting is being held in Basel, Switzerland from
June 22nd to June 26th.
Cerus will also be hosting a satellite symposium on Tuesday,
June 25th from 12:30 pm CEST to 1:30 pm CEST. The symposium will
feature presentations titled Safeguarding the Blood Supply Against
(Re)emerging Pathogens and Balancing Blood Safety and
Economics.
“The clinical body of evidence supporting the use of INTERCEPT
blood products continues to grow as shown by the number of oral
presentations and posters being presented this week at ISBT,” said
Dr. Richard Benjamin, Cerus’ chief medical officer. “The data being
presented at this year’s ISBT will highlight topics including the
operational benefits associated with INTERCEPT treated 7-day
platelets compared to conventional 5-day platelets, the design of a
Phase 1 clinical trial in Africa evaluating INTERCEPT in whole
blood transfusions, and the assessment of INTERCEPT’s efficacy in
reducing the load of viral and bacterial pathogens.”
Key presentations of interest include:
- Toward an Appropriate Pathogen Reduction Technology for
Whole Blood in Resource-Limited Settings: Clinical Development
Plans for the INTERCEPT Blood System for Whole Blood, S Amar, R
Schwabe, A Grzesiczek et al. The Phase 1 study using INTERCEPT in
whole blood is the first step that marks a clinical program that
could bring pathogen reduction technology in resource-limited
regions.
- Efficient Inactivation of Brucella Clinical Isolates in
Human Platelet Concentrates in 100% Plasma with Amotosalen and
Ultraviolet A Light Treatment, F Alseraye, O Alsaweed, F
Albloui et al. INTERCEPT pathogen reduced Brucella in six
isolates.
- Therapeutic Response to Amotosalen/UVA-Treated Platelets
With Up to 7 Days Storage During 5 Years of Routine Practice, L
Infanti, A Holbro, J Passweg et al. Data showed that INTERCEPT
treated platelets older than 5 days was safe and effective to
transfuse to hematology/oncology patients and did not affect
hemostasis.
- How to Prepare the Madrid Region for a Potential Outbreak of
Emergent Pathogens without Increasing Overall Production Cost?,
A Arruga, I Lucea, A Richart et al. The study confirmed the
center’s objective of converting 25% of its production to
pathogen-reduced platelets without increasing the overall
production cost.
- Influence of the Use of 7-Day Platelets Pathogen Inactivated
with Amotosalen/UVA on the Discards Due to Expiry in the
Hemotherapy Area of Castilla La Mancha (Spain), AL Pajares
Herraiz, C Coello de Portugal, MD Morales et al. Improved
forecasting, information technology, and product shelf-life
extension as a result of INTERCEPT treatment contributed to lower
product discards due to expiry at the three hospitals in the
study.
- Efficient Inactivation of MERS-Coronavirus in Human
Apheresis Platelets with Amotosalen and Ultraviolet A Light,
Treatment SI Hindawi, A Hashem, A Hassa et al. Platelet
concentrates spiked with MERS-CoV and treated with INTERCEPT
resulted in a greater than 4 log reduction in plaque forming units
(pfu) per ml. INTERCEPT may be effective in minimizing transfusion
transmitted infections of MERS-CoV.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the
world’s blood supply and aims to become the preeminent global blood
products company. Based in Concord, California, our employees are
dedicated to deploying and suppling vital technologies and
pathogen-protected blood components for blood centers, hospitals
and ultimately patients who rely on safe blood. With the INTERCEPT
Blood System, we are focused on protecting patients by delivering
the full complement of reliable products and expertise for
transfusion medicine. Cerus develops and markets the INTERCEPT
Blood System, and remains the only company in the blood transfusion
space to earn both CE Mark and FDA approval for pathogen reduction
of both platelet and plasma components. Cerus currently markets and
sells the INTERCEPT Blood System in the United States, Europe, the
Commonwealth of Independent States, the Middle East and selected
countries in other regions around the world. The INTERCEPT Red
Blood Cell system is in clinical development. For more information
about Cerus, visit www.cerus.com.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190624005726/en/
Tim Lee – Investor Relations Director Cerus Corporation
925-288-6137
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Sep 2023 to Sep 2024